Benjamin Shaker - Jun 14, 2023 Form 4 Insider Report for agilon health, inc. (AGL)

Role
Chief Markets Officer
Signature
/s/ Steve Meetre, as Attorney-in-Fact
Stock symbol
AGL
Transactions as of
Jun 14, 2023
Transactions value $
-$558,586
Form type
4
Date filed
6/16/2023, 04:14 PM
Previous filing
May 17, 2023
Next filing
Jul 14, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AGL Common Stock Options Exercise $5.55K +1.85K +2.33% $3.00* 81.4K Jun 14, 2023 Direct F1
transaction AGL Common Stock Sale -$33.2K -1.85K -2.27% $17.93 79.5K Jun 14, 2023 Direct F1, F2, F3
transaction AGL Common Stock Options Exercise $59.9K +15.8K +19.86% $3.79* 95.3K Jun 14, 2023 Direct F1
transaction AGL Common Stock Sale -$294K -15.8K -16.57% $18.60 79.5K Jun 14, 2023 Direct F1, F2, F4
transaction AGL Common Stock Options Exercise $4.17K +1.1K +1.38% $3.79* 80.6K Jun 14, 2023 Direct F1
transaction AGL Common Stock Sale -$21.1K -1.1K -1.36% $19.17 79.5K Jun 14, 2023 Direct F1, F2, F5
transaction AGL Common Stock Options Exercise $71.1K +18.8K +23.57% $3.79* 98.3K Jun 15, 2023 Direct F1
transaction AGL Common Stock Sale -$351K -18.8K -19.08% $18.73 79.5K Jun 15, 2023 Direct F1, F2, F6

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AGL Options (Right to buy) Options Exercise $0 -1.85K -100% $0.00* 0 Jun 14, 2023 Common Stock 1.85K $3.00 Direct F7
transaction AGL Options (Right to buy) Options Exercise $0 -15.8K -3.51% $0.00 434K Jun 14, 2023 Common Stock 15.8K $3.79 Direct F8
transaction AGL Options (Right to buy) Options Exercise $0 -1.1K -0.25% $0.00 433K Jun 14, 2023 Common Stock 1.1K $3.79 Direct F8
transaction AGL Options (Right to buy) Options Exercise $0 -18.8K -4.33% $0.00 414K Jun 15, 2023 Common Stock 18.8K $3.79 Direct F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes restricted stock units.
F2 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan effective September 15, 2022.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $17.665 to $18.040, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $18.040 to $19.030, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $19.055 to $19.295, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $18.2600 to $19.100, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
F7 These options were granted on April 27, 2017, and became fully vested as of September 14, 2021.
F8 These options were granted on February 9, 2019, and became fully vested as of February 9, 2023.